Thermo Fisher Scientific have further cemented their reputation as a serial acquirer with the purchase of FEI Company for approximately $4.2B in cash. Oregon-based FEI Company are world leaders in
A recent mixed securities shelf registration filing by Thermo Fisher Scientific has prompted speculation from industry insiders and investors, with prominent advisors predicting further acquisitions for the company throughout 2016
The UK’s Human Fertilisation and Embryology Authority (HFEA) has given the go-ahead for a select group of Francis Crick Institute researchers to edit the genomes of human embryos. The group,
Advanced Cell Diagnostics and Leica Biosystems have announced a comprehensive partnership to develop and commercialise tissue-based diagnostic tests based on ACD’s RNAscope in situ hybridisation (ISH) assays and Leica’s clinical
Thermo Fisher Scientific (NYSE:TMO) have announced an agreement to acquire Affymetrix (NASDAQ:AFFX) for approximately $1.3 billion, or $14.00 per share, in cash. The acquisition was unanimously approved by the boards
Last month researchers at Washington University in St. Louis announced the ongoing development of ViroCap, a novel test capable of detecting nearly all viruses known to infect humans and animals.
On August 31, 2015 Google Life Sciences and French pharma giant Sanofi announced that the two companies will work together on new digital technology and tools for the treatment of
Evolution’s 2015 Biopharmaceutical IPO Analysis was featured in a recent article on Forbes. Science & Business correspondent Arlene Weintraub’s article, titled “Will Wall Street Volatility Dampen The Sizzling Biotech IPO
In the first half of 2015 fifty therapeutics companies finalised their IPOs, raising over $5.17 billion across multiple global exchanges. Evolution Global Talent Attraction analysed the therapeutic targets and IPO
Merck Millipore and Singulex, the developer and leading provider of Single Molecule Counting (SMC™) technology for clinical diagnostics and scientific discovery, have announced that they have entered into a definitive
Advanced Cell Diagnostics (ACD) have raised a further $22 million in Series C equity financing, with proceeds to be used to accelerate their entry into the research and clinical diagnostics
Sigma-Aldrich’s acquisition by Merck has been conditionally cleared by the European Commission, and has received full clearance from the Chinese Ministry of Commerce. Merck and Sigma have already cleared from
Evolution founder and Managing Director Dr. Jason Beckwith was recently featured on monthly Genetic Engineering & Biotechnology News column JobWatch. Dr. Beckwith offered GEN an insight into the hiring practices
Udit Batra has been appointed to lead the combined life science business of Merck Millipore and Sigma-Aldrich once the acquisition of Sigma-Aldrich has been successfully completed later this year. Udit
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, announced financial results today for the fourth quarter and fiscal year ended
